Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients

Table 1

HCC patient demographics.

Pt.	Dose DC	Risk Factor	Stage	Previous treatments^1	Pre-AFP (ng/mL)	Post-AFP; (ng/mL)	Response^2	PFS^3; (mo)	OS^4; (mo)
A1	1 × 10^6	?	IVb	Chemoembo, CDDP, Adriamycin, 5-FU, Xeloda, Thalidomide	2.811	2.748 (+28)	PD	0	4
A2	1 × 10^6	HBV	IVa	Chemoembo	4.740	5.770; (d + 28)	PD	0	20
A3^5	1 × 10^6	EtOH	IVa	RFA	3.080	(no DC)	(no DC)	0	2
A4^6	1 × 10^6	HCV	IVb	—	10,800	10.650	(1 vaccine)	0	—
B2	1 × 10^6	?	IVa	Surgery	5.100	7.650; (d + 35)	PD	0	4
B3^7	5 × 10^6	HCV	IVa	Chemoembo RFA	102	65; (d + 28)	NE	0	35
B5	5 × 10^6	HBV	IVa	Chemoembo, CarboTaxol, Xeloda	1.630	2.515; (d + 112)	PD	0	3+
B8	5 × 10^6	HCV	IVb	Chemoembo	96.7	134	PD	0	5+

¹Previous treatments received (chemoembo, chemoembolization; CDDP, cis-platin; 5-FU, 5-flouro-uracil; Xeloda, capecitabine; RFA, radiofrequency ablation; carbo, carboplatin; XRT, radiation therapy).
²PD: progressive disease, NE: no evidence of disease.
³PFS: progression free survival.
⁴OS: overall survival.
⁵No DC: no DC vaccines could be generated which passed clinical protocol release criteria.
⁶1 vaccine: patient progressed early and did not receive the 3 DC vaccinations.
⁷ NE: patient B3 responded to chemoembolization and RFA and was vaccinated shortly thereafter, and had 35 mo. OS.